Caring Ambassadors Program

Hepatitis C Newsletter

www.HepCChallenge.org

 

October 2012

 

 

Clinical Trials, Cohort Studies, Pilot Studies

 

Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. Weintraub SJ, Fleckenstein JF, Marion TN, et al. Am J Clin Nutr. 2012 Sep 26. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23015322

 

African Americans are less likely to have clearance of hepatitis C virus infection: the findings from recent u.s. Population data. Mir HM, Stepanova M, Afendy M, Kugelmas M, Younossi ZM. J Clin Gastroenterol. 2012 Sep;46(8):e62-5.

http://www.ncbi.nlm.nih.gov/pubmed/22178959

 

Perceived Barriers to Hepatitis C Therapy for Patients Receiving Opioid Agonist Treatment. Zickmund SL, Campbell SA, Tirado CF, Zook CL, Weinrieb RM. J Addict Med. 2012 Sep;6(3):233-239.

http://www.ncbi.nlm.nih.gov/pubmed/22790464

 

Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Treitel M, Marbury T, Preston RA, et al. Clin Pharmacokinet. 2012 Sep 1;51(9):619-28. doi: 10.2165/11633440-000000000-00000.

http://www.ncbi.nlm.nih.gov/pubmed/22799589

 

Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. Atsukawa M, Tsubota A, Kondo C, et al. J Gastroenterol Hepatol. 2012 Sep 18. doi: 10.1111/j.1440-1746.2012.07267.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22989264

 

IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, et al. Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T.

http://www.ncbi.nlm.nih.gov/pubmed/23002361

 

Baseline characteristics and mortality among people in care for chronic viral hepatitis: The Chronic Hepatitis Cohort Study (CHeCS). Moorman AC, Gordon SC, Rupp LB, Spradling PR, et al. . Clin Infect Dis. 2012 Sep 18. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22990852

 

Quantifying the fraction of cirrhosis attributable to alcohol among chronic HCV patients: Implications for treatment cost-effectiveness. Innes HA, Hutchinson SJ, Barclay S, et al. Hepatology. 2012 Sep 7. doi: 10.1002/hep.26051. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22961861

 

Variability of hepatitis C virus hypervariable region 1 (HVR-1) during the early phase of pegylated interferon and ribavirin therapy. Caraballo CK, Laskus T, Bukowska-Ośko I, et al. Adv Med Sci. 2012 Sep 11:1-5. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22968340

 

Basic and Applied Science, Pre-Clinical Studies

 

Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection. Higashitani K, Kanto T, Kuroda S, et al. J Gastroenterol. 2012 Sep 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22976933

 

Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy. Nomura H, Miyagi Y, Tanimoto H, Yamashita N, Ito K, Masaki N, Mizokami M. J Gastroenterol Hepatol. 2012 Sep;27(9):1461-6. doi: 10.1111/j.1440-1746.2012.07171.x.

http://www.ncbi.nlm.nih.gov/pubmed/22554247

 

Hepatitis C virus NS3/4A protease blocks IL-28 production. Ding Q, Huang B, Lu J, Liu YJ, Zhong J. Eur J Immunol. 2012 Sep;42(9):2374-82. doi: 10.1002/eji.201242388.

http://www.ncbi.nlm.nih.gov/pubmed/22685015

 

CD4(+) and CD8(+) Regulatory T Cells (Tregs) are Elevated and Display an Active Phenotype in Patients with Chronic HCV Mono-Infection and HIV/HCV Co-Infection.

Hartling HJ, Gaardbo JC, Ronit A, et al. Scand J Immunol. 2012 Sep;76(3):294-305. doi: 10.1111/j.1365-3083.2012.02725.x.

http://www.ncbi.nlm.nih.gov/pubmed/22671952

 

Towards a Hepatitis C Vaccine: the Structural Basis of Hepatitis C Virus Neutralization by AP33, a Broadly Neutralizing Antibody. Potter JA, Owsianka AM, Jeffery N, et al. J Virol. 2012 Sep 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22993159

 

Regulation of hepatitis C virus replication and gene expression by the MAPK-ERK pathway. Pei R, Zhang X, Xu S, Meng Z, Roggendorf M, Lu M, Chen X. Virol Sin. 2012 Sep 21. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23001481

 

HIV/HCV Coinfection

 

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. Weimer LE, Fragola V, Floridia M, et al. J Antimicrob Chemother. 2012 Sep 14. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22984206

 

Buprenorphine for Human Immunodeficiency Virus/Hepatitis C Virus-coinfected Patients: Does It Serve as a Bridge to Hepatitis C Virus Therapy? Taylor LE, Maynard MA, Friedmann PD, et al. J Addict Med. 2012 Sep;6(3):179-85.

http://www.ncbi.nlm.nih.gov/pubmed/22614935

 

Atazanavir-based antiretroviral therapy is associated with higher hepatitis C virus viral load in HIV/hepatitis C virus patients. Rivero-Juarez A, Mira JA, Santos I, et al. AIDS Res Hum Retroviruses. 2012 Sep 11. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22966845

 

The influence of hepatitis B virus on antiviral treatment with interferon and ribavirin in Asian patients with hepatitis C virus/hepatitis B virus coinfection: a meta-analysis. Liu JY, Sheng YJ, Hu HD, et al. Virol J. 2012 Sep 6;9(1):186. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22950520

 

A prospective evaluation of pulmonary, systemic and hepatic hemodynamics in HIV-HCV coinfected patients prior and after antiviral therapy with pegylated interferon and ribavirin. Reiberger T, Payer BA, Ferlitsch A, et al. Antivir Ther. 2012 Sep 5. doi: 10.3851/IMP2349. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22948263

 

Human immunodeficiency virus enhances hepatitis C virus replication by differential regulation of IFN and TGF family genes. Zhang X, Daucher M, Baeza J, Kim CW, Russell R, Kottilil S. J Med Virol. 2012 Sep;84(9):1344-52. doi: 10.1002/jmv.23315.

http://www.ncbi.nlm.nih.gov/pubmed/22825812

 

Epidemiology, Diagnostics, and Miscellaneous Works

 

Chronic Pain Treatment and Health Service Utilization of Veterans with Hepatitis C Virus Infection. Lovejoy TI, Dobscha SK, Cavanagh R, Turk DC, Morasco BJ. Pain Med. 2012 Sep 7. doi: 10.1111/j.1526-4637.2012.01476.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22958315

 

A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010. Dorsey KA, Moritz ED, Steele WR, Eder AF, Stramer SL. Transfusion. 2012 Sep 25. doi: 10.1111/j.1537-2995.2012.03904.x. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/23003320

 

A Comparison of Enrollees Versus Non-enrollees in a Patient/Family HCV Psycho-education Study. Pollio DE, North CS, Hudson AM, Hong BA. J Clin Psychol Med Settings. 2012 Sep 19. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22990747

 

Liver Cancer

 

Effect of type 2 diabetes on risk for malignancies included hepatocellular carcinoma in chronic hepatitis C. Arase Y, Kobayashi M, Suzuki F, et al. Hepatology. 2012 Sep 18. doi: 10.1002/hep.26087. [Epub ahead of print]

http://www.ncbi.nlm.nih.gov/pubmed/22991257

 

Deficiency of the promyelocytic leukemia protein fosters hepatitis C-associated hepato-carcinogenesis in mice. Herzer K, Carbow A, Sydor S, et al. PLoS One. 2012;7(9):e44474. Epub 2012 Sep 11.

http://www.ncbi.nlm.nih.gov/pubmed/22984515

 

Recent Trends of Japanese Hepatocellular Carcinoma due to HCV in Aging Society. Hiraoka A, Hidaka S, Shimizu Y, et al. Hepatogastroenterology. 2012 Sep;59(118):1893-5. doi: 10.5754/hge11732.

http://www.ncbi.nlm.nih.gov/pubmed/22193439

 

A Comparative Analysis of Hepatocellular Carcinoma after Hepatic Resection in Young versus Elderly Patients. Lee CR, Lim JH, Kim SH, et al. J Gastrointest Surg. 2012 Sep;16(9):1736-43. Epub 2012 Jul 19.

http://www.ncbi.nlm.nih.gov/pubmed/22810298